• Rate and extent of absorption [ Time Frame: 120 hours (5 days) ] [ Designated as safety issue: No ]
• Safety [ Time Frame: signing of informed consent to 30 days after last study visit ] [ Designated as safety issue: Yes ]

To evaluate the effect of food on the rate and extent of absorption of megestrol acetate 625 mg/5 mL , and determine the safety and tolerability of megestrol acetate 625 mg/5 mL in healthy individuals.

• Pharmacokinetics
• Bioavailability

• Experimental: Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) with a high fat meal
• Active Comparator: Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) following an overnight fast

Inclusion Criteria:

• Body weight ranging from 60-100 kg (132-220 lbs) and body mass index ≥18 and ≤32
• Healthy

Exclusion Criteria:

• History of or any current medical conditions that could interfere with drug consumption, absorption, distribution, metabolism (eg. CYP450 inducers or inhibitors), or excretion of study drug
• History of or any current medical conditions that could affect subject safety
• History of frequent nausea or emesis, regardless of etiology
• Participation in a clinical drug study during the 30 days preceding the initial dose
• Significant illness during the 4 weeks preceding study entry
• Use of any medication, including vitamins/herbal/mineral supplements, during the 7 days preceding the initial dose
• Refusal or inability to abstain from food 10 hours proceeding and 4 hours following study drug administration, to consume the FDA high fat meal as directed, and to abstain from caffeine- or xanthine-containing beverages entirely during each confinement
• Any history of or current drug or alcohol abuse
• Prior alcohol intake exceeding the equivalent of 14 units/week (12 oz beer = 4 oz wine = 1.5 oz shot = 1 unit) on average, or consumption of any alcoholic beverages within 48 hours of study drug administration
• History of smoking>25 cigarettes/day within 45 days of study drug administration
• Blood or blood products donated within 30 days prior to study drug administration, or anytime during the study, except as required by this protocol
• Positive results of urine drug screen, blood alcohol by a Breathalyzer test, hepatitis B surface antigen, hepatitis B surface antibody (unless immunized), or anti-HCV